REVB Revelation Biosciences
- 1.8300
- -0.0800-4.19%
Revelation Biosciences News
12 Health Care Stocks Moving In Friday's After-Market Session
GainersAkso Health Group (NASDAQ:AHG) shares rose 11.4% to $0.79 during Friday's after-market session. The company's market cap stands at $116.0 million. China SXT Pharmaceuticals (NASDAQ:SXTC) shares
Revelation Biosciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 EPS Results.
Revelation Biosciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 EPS Results.
Revelation Biosciences (REVB.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -$2.46, previous value of -$15.30, expected value of -$1.77.
Revelation Biosciences (REVB.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -$2.46, previous value of -$15.30, expected value of -$1.77.
Revelation Biosciences 1Q Loss/Shr $2.46 >REVB
Revelation Biosciences 1Q Loss/Shr $2.46 >REVB
Revelation Biosciences Q1 EPS $(2.46) Misses $(1.77) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.46) per share which missed the analyst consensus estimate of $(1.77) by 38.98 percent. This is a 83.92 percent increase over losse
Press Release: Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 SAN DIEGO--(BUSINESS WIRE)--May 10, 2024-- Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Compan
10-Q: Quarterly report
Navigating Uncertainty: How Healthcare Reforms Pose Risks to Revelation Biosciences Inc.
Revelation Biosciences Q4 EPS $(8.33) Beats $(13.77) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(8.33) per share which beat the analyst consensus estimate of $(13.77) by 39.51 percent. This is a 84.31 percent increase over losses
Revelation Biosciences Sees Funding Sufficient Through 2024 >REVB
Revelation Biosciences Sees Funding Sufficient Through 2024 >REVB
Revelation Biosciences 4Q Loss/Shr $8.33 >REVB
Revelation Biosciences 4Q Loss/Shr $8.33 >REVB
Press Release: Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 SAN DIEGO--(BUSINESS WIRE)--March 22, 2024-- Revelation Biosciences, Inc. (NASDAQ: RE
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersGeron (NASDAQ:GERN) stock increased by 90.8% to $3.34 during Thursday's after-market session. The market value of their outstanding shares is at $1.8 billion. Madrigal Pharmaceuticals (NASDAQ:M
Solid Biosciences, Cue Biopharma, Annexon Among Healthcare Movers
Revelation Biosciences Presented Data Showing Pretreatment With Gemini, Improved Kidney Function With Reduced Serum Blood Urea Nitrogen And Creatinine, Urine C-reactive Protein, And Acute Kidney Injury-Related Inflammation
Gemini is the company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) for systemic administration. It is being developed as a potential therapy for prevention and treatment o
Revelation Biosciences Showcases Research at Nephrology Conference
ETRN, CRDF and KC Are Among Pre Market Gainers
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
-Top-line data including safety, tolerability, and biomarker activity anticipated this summer- -This Phase 1 clinical study data will support further development across multiple indications- Revelation Biosciences
OCGN, NEO and FRSX Are Among Pre Market Gainers
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
Analysis
Price Target
No Data
